Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
about
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Systemic treatment for inoperable pancreatic adenocarcinoma: review and updateUltrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic CancerFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerUpdate on the management of pancreatic cancer: surgery is not enoughEfficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trialsGemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Personalising pancreas cancer treatment: When tissue is the issue.MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic ReviewErlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national databaseMeta-analyses of treatment standards for pancreatic cancer.Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.Pancreatic cancer - cost for overtreatment with gemcitabine.PIM kinases: an overview in tumors and recent advances in pancreatic cancer.Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.Advanced pancreatic cancer: The standard of care and new opportunitiesStereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury
P2860
Q26747695-A1253192-3B80-4805-BF8E-8265F2306C7DQ26830913-189A5522-018C-4A58-B52E-5E2727196BC8Q27300789-3BB9A40A-A8E5-4A83-B9E1-6F6DE25BE951Q28075540-64D6C8C3-065A-406D-9C3F-2CA59DAFD13AQ28087060-1259F428-D9E9-4E20-A000-D114F699D76CQ33416894-70A15189-612C-4D48-BC9D-1A2BC74809FEQ33421322-99A35E51-FBB1-4D04-8782-E03905419261Q33440500-4E73AB21-9EB4-4EF2-B161-C0A7622FDF2DQ33801384-A4DEFE91-7AC8-42EB-A15A-50543775E756Q34334470-407E32A3-7B2B-4575-8E82-F657F13989ABQ34632760-A2E14835-9B02-4245-8D72-338FFD67677FQ35651591-5F7FCA62-5225-4DFA-ADD1-2B938736C0ADQ35871195-BF0A4E04-3829-4DCA-8902-B9B496EF2375Q36072863-0997BEA6-0C92-410F-91A7-A40570DC688EQ36640493-141C0D87-4C5F-4D3F-9FBE-8AD7B7A57844Q37040624-4432FCB3-1CAA-4E92-A539-CB7C0777936EQ37644986-E2916D16-4551-4CDB-A38F-6C7D7FD8AD04Q37711653-310A10F1-C184-4BFA-86F8-DA13FA66250FQ38067828-AADAB944-E343-4E4E-B5E4-1D6F2DA77732Q38209606-B903859D-B149-4D3E-9542-A7B501BD4B42Q38387283-7C7E09CB-7B54-40F8-978F-93863B80F195Q41195992-011472FD-954C-4454-ADFE-6C905481B87DQ45017704-AAF4CEFF-F0B6-411D-AD08-343E3756D2E2Q45902239-A597893F-85DC-4935-A88B-766CB23A514FQ47123105-AA0118E4-ED34-4C34-8E9F-2B95ED9F019CQ48004181-6AB3565A-45E8-48D9-91A4-0356BE88DF08Q48163413-830F804D-E3DA-4661-8501-7C89D6B92581Q48219198-4C606047-AA8E-43C9-9379-FC2670782A0CQ54959277-4933B34F-EA47-4068-ACFE-88117A0F1169Q57822243-9CDBF94C-15EB-41FF-8DCF-18CA36062A0FQ59049588-233ABAD7-0E0B-4019-93F1-4C1DAD030BCE
P2860
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@ast
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@en
type
label
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@ast
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@en
prefLabel
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@ast
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@en
P2093
P2860
P356
P1476
Does gemcitabine-based combina ...... nresectable pancreatic cancer?
@en
P2093
Daniel Ansari
De-Quan Wu
Roland Andersson
P2860
P304
P356
10.3748/WJG.V18.I35.4944
P407
P577
2012-09-01T00:00:00Z